+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Endometriosis Treatment Market by Treatment Type, Drug Class, Route of Administration, Distribution Channel, and by Region - Global Forecast to 2022-2033

  • PDF Icon

    Report

  • 200 Pages
  • January 2023
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5717251
The endometriosis treatment market size is estimated to be USD 1,525.12 million in 2022 and is expected to witness a CAGR of 13.87% during the forecast period 2023-2033. Government and major market participants constantly invest in R&D and acquire funds on a national and worldwide level and increase in public knowledge of the disease are some of the factors contributing to the market growth. Additionally, strong late-stage product pipeline, expanding endometriosis prevalence, and growing women's health awareness are other factors supporting the market growth. However, is expected to hinder the growth.

Government and major market participants constantly invest in R&D and acquire funds on a national and worldwide level is expected to propel the market growth during the projected period. For instance, the U.S. federal government announced in March 2022 that NICHD would receive USD 92 million in funding for endometriosis research. Similar to this, the Endometriosis Clinical and Genetic Research in India (ECGRI) initiative received a USD 0.47 million funding from the DBT Wellcome India Alliance in February 2021. This ECGRI research is clinical research on the genetic predispositions and phenotypes of endometriosis.

Increase in public knowledge of the disease is predicted to fuel the market growth during the forecast period. Endometriosis awareness campaigns are held annually in March in a number of nations to increase public knowledge of the disease. For instance, on March 12th, Austria will host a free, full-day online congress to share knowledge among endometriosis experts. A virtual conference titled 'Myths and truths about the disease' was held on March 19 and 20, 2022, by the Endometriosis and Reproductive Health Foundation in Bulgaria. Experts in the area refute sickness myths in these forums. In a similar vein, Canada, Bangladesh, Finland, France, Hungary, India, and many other nations throughout the world have organised a number of events to promote open discussions about endometriosis. As a result, these activities are pushing the market for endometriosis treatment.

By Treatment Type

The market is categorized into hormone therapy and pain medication. In the global market, the pain medication segment accounted for the largest revenue share in 2022 owing to the patients with endometriosis suffer unpleasant symptoms including dysmenorrhea and dyspareunia, persistent pelvic discomfort, infertility, and emotional distress, among others. Drugs that reduce severe disease symptoms so gradually reduce their harmful effects on mental health and quality of life. The market is being driven by this medication due to its fewer side effects, good tolerance, affordable costs, and a high safety profile. Nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen (Advil, Motrin IB, and others), paracetamol, and naproxen are among the most popular medication classes (Aleve). The market for hormone therapy is anticipated to grow at a CAGR of 13.99% over the forecast period. The expansion of the hormone therapy market is anticipated to be fuelled by popular therapeutic products including Yselty (linzagolix) from ObsEva and Myovant/Relugolix Pfizer's combination tablet. In addition, strategic collaboration between important players is expected to propel market expansion.

By Drug Class

The market is divided into gonadotropin releasing hormone, NSAIDs, oral contraceptive, and others. In 2022, the NSAIDs segment accounted for the highest revenue share due to fast pain relief, the first line of therapy, available at an affordable price, and being available in both over-the-counter and prescription forms. Paracetamol, ibuprofen, and naproxen are types of nonsteroidal anti-inflammatory medicines that decrease mild to moderate pain by preventing the synthesis of prostaglandins. Gonadotropin-releasing hormone (GnRH) medicines are expected to dominate the market over the projected period. The dosage forms include tablets, injections, shots, and nasal sprays. The first drug for treating disease-related pain was Orilissa (elagolix), made by AbbVie Inc. Patients who are resistive to first therapy are advised to try Zoladex, Lupron, Orilissa, or Synarel, which are GnRH agonists and antagonists. The key advantage of the treatment is that after it is finished, the woman resumes having regular menstrual periods, and her ability to conceive is unaffected.

By Route of Administration

The market is categorized into injectable, oral, and others. In the global market, the oral segment accounted for the largest revenue share in 2022 owing to the widespread and practical method of administration for painkillers, their high bioavailability, and their effectiveness in hormone therapy. The oral method of administration, which comprises NSAIDs, oral contraceptives, oral progestins including Aygestin and Provera, and oral GnRH agonists, is fueling the segment's expansion. The segment is also being fuelled by innovative therapies including AbbVie's Orilissa (elagolix), the first GnRH antagonist to be taken orally for the treatment of endometriosis. The other route of administration is anticipated to grow at a significant CAGR over the projection period. The availability of topical formulations as cutting-edge transdermal medication delivery techniques can be attributed to this. By outperforming first pass metabolism, they show improved efficacy. Contraceptive patches including Twirla and Xulane are featured in the segment. Important companies are also showing interest in creating such a transdermal system, which is promoting the expansion of the market. For instance, Noven Pharmaceutical created CombiPatch, a combination patch containing norethindrone acetate and estrogen to treat endometriosis.

By Distribution Channel

The market is divided into retail pharmacy, hospital pharmacy, online pharmacy, and others. In 2022, the retail pharmacy segment accounted for the largest revenue share owing to fact that most endometriosis patients treat patients outside of a hospital setting and that over-the-counter drugs are widely available. Increasing prescriptions for endometriosis drugs, rising public knowledge of the condition, and surge in healthcare costs are further factors driving market expansion. A moderate expansion is anticipated in the hospital pharmacy segment over the forecast period. The hospital pharmacy market is primarily driven by the growing demand of endometriosis therapy as an alternative to surgery. Hospital pharmacists can also help endometriosis patients and their caretakers choose the right medications due to their knowledgeable about medications. Such factors all promote segment growth.

Regional Markets

In 2022, North America region accounted for the highest revenue in the endometriosis treatment market and is expected to maintain its dominance during the forecast period. This is attributed to the increasing endometriosis prevalence, growing disease awareness in this area, and the accessibility of high-tech products. The market for endometriosis treatments is expanding in part due to the approval of innovative products and their subsequent launches. For instance, in August 2022, the FDA approved Myfembree from Myovant Sciences and Pfizer for use as a pain management drug in premenopausal women with the condition. Asia Pacific is anticipated to experience growth at a significant rate over the forecast period. The increase in disease cases and the strategic actions made by market participants for regional expansion in such places are credited with the region's growth. Additionally, it is projected that rising research and development and rising investments to create and market such new delivery methods will accelerate market expansion in the region.

Competitor Insights

Some of the key players operating in the endometriosis treatment market are AstraZeneca, Teva Pharmaceutical Industries, ObsEva SA, Pfizer, Inc., AbbVie, Inc, Zydus Healthcare Limited, Bayer AG, Eli Lilly and Company, Akorn, Inc., and Astellas Pharma Inc.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

For instance, Theramex and ObsEva SA announced their strategic licencing partnership to support Linzagolix's global market expansion and commercialization in February 2022.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including treatment type, drug class, route of administration, and distribution channel from 2023 to 2033.

Segmentation: Endometriosis Treatment Market Report 2022 - 2033

Treatment Type (Revenue, USD Million), 2022 - 2033

  • Hormone Therapy
  • Pain Medication

Drug Class (Revenue, USD Million), 2022 - 2033

  • Gonadotropin Releasing Hormone
  • NSAIDs
  • Oral Contraceptive
  • Others

Route of Administration (Revenue, USD Million), 2022 - 2033

  • Injectable
  • Oral
  • Others

Distribution Channel (Revenue, USD Million), 2022 - 2033

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy
  • Others

By Region (Revenue, USD Million), 2022 - 2033

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Framework
1.3.1. Research Models
1.3.1.1. Bottom-up Approach
1.3.1.2. Top-down Approach
1.3.1.3. Data Triangulation
1.3.2. Data Analysis
1.3.2.1. Data Validation
1.3.2.2. Market Size Estimation
1.3.2.3. Market Forecast Model

2. Introduction: Endometriosis Treatment

3. Executive Summary

4. Market Dynamics
4.1. Market Drivers
4.1.1. Driver 1
4.1.2. Driver 2
4.1.3. Driver 3
4.1.4. Driver 4
4.1.5. Driver 5
4.2. Market Restraint
4.2.1. Restraint 1
4.2.2. Restraint 2
4.2.3. Restraint 3
4.2.4. Restraint 4
4.3. Market Opportunities
4.3.1. Opportunity 1
4.3.2. Opportunity 2
4.3.3. Opportunity 3
4.3.4. Opportunity 4
4.4. Market Trends
4.4.1. Trend 1
4.4.2. Trend 2
4.4.3. Trend 3
4.4.4. Trend 4
4.5. Market Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
4.5.3. Challenge 3
4.5.4. Challenge 4

5. Market Environment Analysis
5.1. Porter’s 5 Forces Analysis
5.2. PESTEL Analysis
5.3. SWOT Analysis

6. COVID-19 Impact Analysis: Endometriosis Treatment Market

7. Market Analysis by Treatment Type
7.1. Hormone Therapy
7.1.1. Hormone Therapy Market Forecast, 2022-2033 (USD Million)
7.2. Pain Medication
7.2.1. Pain Medication Market Forecast, 2022-2033 (USD Million)

8. Market Analysis by Drug Class
8.1. Gonadotropin Releasing Hormone
8.1.1. Gonadotropin Releasing Hormone Market Forecast, 2022-2033 (USD Million)
8.2. NSAIDs
8.2.1. NSAIDs Market Forecast, 2022-2033 (USD Million)
8.3. Oral Contraceptive
8.3.1. Oral Contraceptive Market Forecast, 2022-2033 (USD Million)
8.4. Others
8.4.1. Others Market Forecast, 2022-2033 (USD Million)

9. Market Analysis by Route of Administration
9.1. Injectable
9.1.1. Injectable Market Forecast, 2022-2033 (USD Million)
9.2. Oral
9.2.1. Oral Market Forecast, 2022-2033 (USD Million)
9.3. Others
9.3.1. Others Market Forecast, 2022-2033 (USD Million)

10. Market Analysis by Distribution Channel
10.1. Retail Pharmacy
10.1.1. Retail Pharmacy Market Forecast, 2022-2033 (USD Million)
10.2. Hospital Pharmacy
10.2.1. Hospital Pharmacy Market Forecast, 2022-2033 (USD Million)
10.3. Online Pharmacy
10.3.1. Online Pharmacy Market Forecast, 2022-2033 (USD Million)
10.4. Others
10.4.1. Others Market Forecast, 2022-2033 (USD Million)

10. Regional Market Analysis
10.2. Regional Market Trends

11. North America Endometriosis Treatment Market
10.1. North America Endometriosis Treatment Market
10.1.1. North America Market Size and Forecast, 2022-2033 (USD Million)
10.1.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
10.1.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.1.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
10.1.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.2. U.S. Endometriosis Treatment Market
10.2.1. U.S. Market Size and Forecast, 2022-2033 (USD Million)
10.2.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
10.2.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.2.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
10.2.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.3. Canada Endometriosis Treatment Market
10.3.1. Canada Market Size and Forecast, 2022-2033 (USD Million)
10.3.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
10.3.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.3.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
10.3.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)

11. Europe Endometriosis Treatment Market
11.1. Europe Endometriosis Treatment Market
11.1.1. Europe Market Size and Forecast, 2022-2033 (USD Million)
11.1.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
11.1.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.1.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
11.1.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.2. Germany Endometriosis Treatment Market
11.2.1. Germany Market Size and Forecast, 2022-2033 (USD Million)
11.2.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
11.2.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.2.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
11.2.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.3. UK Endometriosis Treatment Market
11.3.1. UK Market Size and Forecast, 2022-2033 (USD Million)
11.3.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
11.3.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.3.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
11.3.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.4. France Endometriosis Treatment Market
11.4.1. France Market Size and Forecast, 2022-2033 (USD Million)
11.4.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
11.4.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.4.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
11.4.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.5. Spain Endometriosis Treatment Market
11.5.1. Spain Market Size and Forecast, 2022-2033 (USD Million)
11.5.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
11.5.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.5.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
11.5.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.6. Italy Endometriosis Treatment Market
11.6.1. Italy Market Size and Forecast, 2022-2033 (USD Million)
11.6.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
11.6.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.6.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
11.6.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.7. Rest of EuropeEndometriosis Treatment Market
11.7.1. Rest of Europe Market Size and Forecast, 2022-2033 (USD Million)
11.7.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
11.7.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.7.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
11.7.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)

12. Asia PacificEndometriosis Treatment Market
12.1. Asia PacificEndometriosis Treatment Market
12.1.1. Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
12.1.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
12.1.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.1.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
12.1.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.2. Japan Endometriosis Treatment Market
12.2.1. Japan Market Size and Forecast, 2022-2033 (USD Million)
12.2.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
12.2.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.2.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
12.2.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.3. China Endometriosis Treatment Market
12.3.1. China Market Size and Forecast, 2022-2033 (USD Million)
12.3.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
12.3.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.3.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
12.3.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.4. India Endometriosis Treatment Market
12.4.1. India Market Size and Forecast, 2022-2033 (USD Million)
12.4.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
12.4.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.4.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
12.4.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.5. South Korea Endometriosis Treatment Market
12.5.1. South Korea Market Size and Forecast, 2022-2033 (USD Million)
12.5.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
12.5.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.5.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
12.5.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.6. Australia Endometriosis Treatment Market
12.6.1. Australia Market Size and Forecast, 2022-2033 (USD Million)
12.6.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
12.6.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.6.1.3. Market Size and Forecast by Route of Administration 2022-2033 (USD Million)
12.6.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.7. Rest of Asia Pacific Endometriosis Treatment Market
12.7.1. Rest of Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
12.7.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
12.7.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.7.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
12.7.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)

13. Latin America Endometriosis Treatment Market
13.1. Latin America Endometriosis Treatment Market
13.1.1. Latin America Market Size and Forecast, 2022-2033 (USD Million)
13.1.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
13.1.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.1.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
13.1.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
13.2. BrazilEndometriosis Treatment Market
13.2.1. Brazil Market Size and Forecast, 2022-2033 (USD Million)
13.2.1.1. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
13.2.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.2.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
13.2.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
13.3. MexicoEndometriosis Treatment Market
13.3.1. Mexico Market Size and Forecast, 2022-2033 (USD Million)
13.3.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
13.3.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.3.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
13.3.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
13.4. Argentina Endometriosis Treatment Market
13.4.1. Argentina Market Size and Forecast, 2022-2033 (USD Million)
13.4.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
13.4.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.4.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
13.4.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
13.5. Rest of Latin America Endometriosis Treatment Market
13.5.1. Rest of Latin America Market Size and Forecast, 2022-2033 (USD Million)
13.5.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
13.5.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.5.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
13.5.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)

14. MEAEndometriosis Treatment Market
14.1. MEA Endometriosis Treatment Market
14.1.1. MEA Market Size and Forecast, 2022-2033 (USD Million)
14.1.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
14.1.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
14.1.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
14.1.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
14.2. GCC Endometriosis Treatment Market
14.2.1. GCC Market Size and Forecast, 2022-2033 (USD Million)
14.2.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
14.2.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
14.2.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
14.2.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
14.3. South Africa Endometriosis Treatment Market
14.3.1. South Africa Market Size and Forecast, 2022-2033 (USD Million)
14.3.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
14.3.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
14.3.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
14.3.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
14.4. Rest of MEA Endometriosis Treatment Market
14.4.1. Rest of MEA Market Size and Forecast, 2022-2033 (USD Million)
14.4.1.1. Market Size and Forecast by Treatment Type, 2022-2033 (USD Million)
14.4.1.2. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
14.4.1.3. Market Size and Forecast by Route of Administration, 2022-2033 (USD Million)
14.4.1.4. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)

15. Competitor Analysis
15.1. Market Share Analysis, 2022
15.2. Major Recent Developments, 2019-2022

16. Company Profiles
16.1. AstraZeneca
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Analysis
16.1.4. Product Benchmarking
16.1.5. Recent Developments
16.2. Teva Pharmaceutical Industries
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Analysis
16.2.4. Product Benchmarking
16.2.5. Recent Developments
16.3. ObsEva SA
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Analysis
16.3.4. Product Benchmarking
16.3.5. Recent Developments
16.4. Pfizer, Inc.
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Analysis
16.4.4. Product Benchmarking
16.4.5. Recent Developments
16.5. AbbVie, Inc.
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Analysis
16.5.4. Product Benchmarking
16.5.5. Recent Developments
16.6. Zydus Healthcare Limited
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Analysis
16.6.4. Product Benchmarking
16.6.5. Recent Developments
16.7. Bayer AG
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Analysis
16.7.4. Product Benchmarking
16.7.5. Recent Developments
16.8. Eli Lilly and Company
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Analysis
16.8.4. Product Benchmarking
16.8.5. Recent Developments
16.9. Akorn, Inc
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Analysis
16.9.4. Product Benchmarking
16.9.5. Recent Developments
16.10. Company 10
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Analysis
16.10.4. Product Benchmarking
16.10.5. Recent Developments
16.11. Company 11
16.11.1. Company Snapshot
16.11.2. Company Overview
16.11.3. Financials
16.11.4. Drug Class Benchmarking
16.11.5. Recent Developments
16.12. Company 12
16.12.1. Company Snapshot
16.12.2. Company Overview
16.12.3. Financials
16.12.4. Drug Class Benchmarking
16.12.5. Recent Developments
16.13. Company 13
16.13.1. Company Snapshot
16.13.2. Company Overview
16.13.3. Financials
16.13.4. Drug Class Benchmarking
16.13.5. Recent Developments
16.14. Company 14
16.14.1. Company Snapshot
16.14.2. Company Overview
16.14.3. Financials
16.14.4. Drug Class Benchmarking
16.14.5. Recent Developments
16.15. Company 15
16.15.1. Company Snapshot
16.15.2. Company Overview
16.15.3. Financials
16.15.4. Drug Class Benchmarking
16.15.5. Recent Developments
16.16. Others Prominent Players

17. Conclusion & Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AstraZeneca
  • Teva Pharmaceutical Industries
  • ObsEva SA
  • Pfizer Inc.
  • AbbVie Inc
  • Zydus Healthcare Limited
  • Bayer AG
  • Eli Lilly and Company
  • Akorn Inc.
  • Astellas Pharma Inc.